Operating Lease, Right-of-Use Asset of Lyell Immunopharma, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Lyell Immunopharma, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Lyell Immunopharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $19,912,000, a 46% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Lyell Immunopharma, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,912,000 -$16,750,000 -46% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $20,951,000 -$16,745,000 -44% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $23,570,000 -$15,125,000 -39% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $24,739,000 -$14,924,000 -38% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $36,662,000 -$3,941,000 -9.7% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $37,696,000 -$3,816,000 -9.2% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $38,695,000 -$3,695,000 -8.7% 31 Mar 2024 10-Q 06 May 2024 2024 Q1
Q4 2023 $39,663,000 -$3,579,000 -8.3% 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $40,603,000 -$3,481,000 -7.9% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $41,512,000 -$3,395,000 -7.6% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $42,390,000 -$3,335,000 -7.3% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $43,242,000 -$3,299,000 -7.1% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $44,084,000 -$3,152,000 -6.7% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $44,907,000 -$3,517,000 -7.3% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $45,725,000 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $46,541,000 -$469,000 -1% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $47,236,000 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $48,424,000 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q4 2020 $47,010,000 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.